Icon
+91 94997 68112
Login Register

Advicor - (500,750,1000 mg/20 mg, 1000 mg/40 mg; Tablet, Exte)

Lovastatin and Niacin Abbott
500,750,1000 mg/20 mg, 1000 mg/40 mg; Tablet, Exte
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
Indicated as an adjunct to diet for reduction of elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Table 7), when the response to an appropriate diet has been inadequate.
Yes
**** (****) *** *** ***** ** **** **** ** **** ****** *******- **** **, **** *** *** ************ ********* . **** *** ** ****** **** ****** ****, ****** (*** ******) ******* **** ** ******* ********** ********* **** **** (****) ** ******* *** *******. ***** *** *****-**** ****, **** *** *** ********** ******* **** ** **-******* ******* *** ******* ** **** ** *** ****** ******* ** ******** ********, ** *****'* ********** ************* ** ******** *** ********* ** ********* *** ****** *****. *** ********* **** ******* **** ** ****** ******* ******** ** ******* *** ******* ********* ** ********* ****. ** * ******** *********, **** ****** ** ***** ***** ** *********** ******* *** ******* *** ***. ** ******, *** **** *** **** ** ******* ******* *** *** ********* ******** *** ******** *** ***** ** * ********** ****** *****. ***** ** ** ***** **** ** ***** ***, *** ***** *** *** ****** ** ********* ** **** ****, ***** ** **** **** ****** **** ******* ******* ***** *** **** **** * **** ** ** ******* ******* ******* *****. ****** ******** ***** ** ***, *** *** *** *****'* **** ** ** ******* *** ******** ***** ******* ** ****.
Advicor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
**** (****) ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** (****) *** \ *** ****, **** ******* ******** ******** ** **** **, ****
  1. *** **** : **** (****) ***** * ************ **** ** ************* ** ********** **** ******** **** ** *** ******* **** ** '*** ******.
  2. ***** **** : ****** (*** ******) ***** **** ******* **** (****) ** ******** ******** ***** ** *** **** . (**** *** *** ****** **** ***** ** *** ******* **** ,*** ******* ***** ******** **** *** **** *** ***** ** **** ** *******)
  3. ******** : *** *** **** ***** **** ************ ********. ** * ****** ** ************* ******** ******** ** *** **** ****** * *** **********.
  4. ****/**** **** : *** ******** ******* **** ** ****** ** **** *** * ***** ****** ** ****** ********* *** *** *** *** **** *** **** *** **.
  5. **** : **** ********** ** ** ****** **** *** ***** * ****** *** ********* *********** ***** (***) & * *********** ********** ******* **** (****) ******** ******** ***** ** *** ****, ** ******* **** **** ********* *****, ***** & ****** ******* *******. (**** *** ******* *** ********* ******** *** *** ***** ********* ** ****** *** ***** ******** *** ******** ** ***** ****).
  6. ***** **** : ******* ********** ********* ******* **** & ***: ******* ***** *** ***** **** ****, **** **** **-******* ******* & ******* ** **** ** ****** ******* ** ******** ******** ** ******** *** ********* ** ********* & ****** *****, *** ********* **** ********* **** ** ****** ******* ******** ** ******* & ******* ********* ** ********* ****
  7. *** **, **** : **** ******** ******* ******* ** **

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.